Drug-reponse_Curated
| Compound | ncRNA | ncRNA Type | Pattern | Throughput | Phenotype | Species | Detail |
|---|---|---|---|---|---|---|---|
| Cisplatin | H19 | lncRNA | sensitive | High | Hypopharyngeal Squamous Cell Carcinoma | Homo sapiens | |
| Doxorubicin | H19 | lncRNA | resistant | Low | Breast cancer | Homo sapiens | |
| Verapamil | H19 | lncRNA | resistant | Low | Breast cancer | Homo sapiens | |
| Doxorubicin | H19 | lncRNA | resistant | Low | Leukemia | Homo sapiens | |
| Etoposide | H19 | lncRNA | resistant | Low | Small cell lung cancer | Homo sapiens | |
| Vincristine | H19 | lncRNA | resistant | Low | Leukemia | Homo sapiens | |
| Doxorubicin | H19 | lncRNA | resistant | Low | Hepatocellular carcinoma | Homo sapiens | |
| Cisplatin | H19 | lncRNA | resistant | Low | Lung Adenocarcinoma | Homo sapiens | |
| Crizotinib | H19 | lncRNA | sensitive | High | Non-Small Cell Lung Cancer | Homo sapiens | |
| 1Alpha,25-Dihydroxyvitamin D3 | H19 | lncRNA | resistant | Low | Colorectal Cancer | Homo sapiens | |
| Huaier Extract | H19 | lncRNA | resistant | Low | Breast Cancer | Homo sapiens | |
| Vincristine | H19 | lncRNA | resistant | Low | Gastric Cancer | Homo sapiens | |
| Cisplatin | H19 | lncRNA | resistant | Low | Ovarian Cancer | Homo sapiens | |
| Paclitaxel | H19 | lncRNA | resistant | Low | Breast Cancer | Homo sapiens | |
| Fluorouracil | H19 | lncRNA | sensitive | Low | Hepatocellular Carcinoma | Homo sapiens | |
| Docetaxel | H19 | lncRNA | sensitive | Low | Hepatocellular Carcinoma | Homo sapiens | |
| Paclitaxel | H19 | lncRNA | sensitive | Low | Hepatocellular Carcinoma | Homo sapiens | |
| Vinorelbine | H19 | lncRNA | sensitive | Low | Hepatocellular Carcinoma | Homo sapiens | |
| Oxaliplatin | H19 | lncRNA | resistant | Low | Colorectal Cancer | Homo sapiens | |
| Paclitaxel | H19 | lncRNA | resistant | Low | Triple-Negative Breast Cancer | Homo sapiens | |
| Cisplatin | H19 | lncRNA | resistant | Low | Seminoma | Homo sapiens | |
| Fluorouracil | H19 | lncRNA | resistant | Low | Colorectal Cancer | Homo sapiens | |
| Fulvestrant | H19 | lncRNA | resistant | Low | Breast Cancer | Homo sapiens | |
| Tamoxifen | H19 | lncRNA | resistant | Low | Breast Cancer | Homo sapiens | |
| Tamoxifen | H19 | lncRNA | resistant | Low | Breast Cancer | Homo sapiens | |
| Bortezomib | H19 | lncRNA | resistant | Low | Multiple Myeloma | Homo sapiens | |
| Lapatinib | H19 | lncRNA | sensitive | High | Pan-Cancer | Homo sapiens | |
| Fluorouracil | H19 | lncRNA | resistant | Low | Choriocarcinoma | Homo sapiens | |
| Methotrexate | H19 | lncRNA | resistant | Low | Choriocarcinoma | Homo sapiens | |
| Paclitaxel | H19 | lncRNA | resistant | High | Endometrial Cancer | Homo sapiens | |
| Tamoxifen | H19 | lncRNA | resistant | Low | Breast Cancer | Homo sapiens | |
| Cabergoline | H19 | lncRNA | sensitive | Low | Pituitary Adenoma | Homo sapiens | |
| Trastuzumab | H19 | lncRNA | resistant | Low | Breast Cancer | Homo sapiens | |
| Gefitinib | H19 | lncRNA | resistant | Low | Lung Adenocarcinoma | Homo sapiens | |
| Fluorouracil | H19 | lncRNA | sensitive | Low | Colorectal Cancer | Homo sapiens | |
| Tamoxifen | H19 | lncRNA | resistant | Low | Breast Cancer | Homo sapiens | |
| Doxorubicin | H19 | lncRNA | resistant | Low | Breast Cancer | Homo sapiens | |
| Cisplatin | H19 | lncRNA | resistant | Low | Melanoma | Homo sapiens | |
| Gefitinib | H19 | lncRNA | resistant | Low | Non-Small Cell Lung Cancer | Homo sapiens | |
| Doxorubicin | H19 | lncRNA | resistant | Low | Breast Cancer | Homo sapiens | |
| Paclitaxel | H19 | lncRNA | resistant | Low | Breast Cancer | Homo sapiens | |
| Erlotinib | H19 | lncRNA | sensitive | High | Non-Small Cell Lung Cancer | Homo sapiens | |
| Gefitinib | H19 | lncRNA | sensitive | High | Non-Small Cell Lung Cancer | Homo sapiens | |
| Erlotinib | H19 | lncRNA | resistant | Low | Non-Small Cell Lung Cancer | Homo sapiens | |
| Sorafenib | H19 | lncRNA | resistant | Low | Hepatocellular Carcinoma | Homo sapiens | |
| Paclitaxel | H19 | lncRNA | resistant | Low | Nasopharyngeal Cancer | Homo sapiens | |
| Temozolomide | H19 | lncRNA | resistant | Low | Glioblastoma | Homo sapiens | |
| Bromocriptine | H19 | lncRNA | sensitive | Low | Pituitary Adenoma | Homo sapiens | |
| Cabergoline | H19 | lncRNA | sensitive | Low | Pituitary Adenoma | Homo sapiens | |
| Cabergoline | H19 | lncRNA | sensitive | Low | Prolactinoma | Rattus norvegicus | |
| Bromocriptine | H19 | lncRNA | sensitive | Low | Prolactinoma | Rattus norvegicus | |
| Vincristine | H19 | lncRNA | resistant | Low | Multiple Myeloma | Homo sapiens | |
| Aspirin | H19 | lncRNA | resistant | Low | Cerebral Ischemic Stroke | Homo sapiens | |
| Tamoxifen | H19 | lncRNA | resistant | Low | Breast Cancer | Homo sapiens | |
| Curcumin + Tamoxifen | H19 | lncRNA | resistant | Low | Breast Cancer | Homo sapiens | |
| Cisplatin | H19 | lncRNA | resistant | Low | Laryngeal Squamous Cell Carcinoma | Homo sapiens | |
| Gemcitabine | H19 | lncRNA | sensitive | High | Cholangiocarcinoma | Homo sapiens | |
| Doxorubicin | H19 | lncRNA | resistant | High | Leukemia | Homo sapiens | |
| Oxaliplatin | H19 | lncRNA | resistant | Low | Hepatocellular Carcinoma | Homo sapiens | |
| Imatinib | H19 | lncRNA | resistant | Low | Chronic Myelogenous Leukemia | Homo sapiens | |
| Temozolomide | H19 | lncRNA | sensitive | High | Glioblastoma | Homo sapiens | |
| Tamoxifen | H19 | lncRNA | resistant | Low | Breast Cancer | Homo sapiens | |
| Enzalutamide | H19 | lncRNA | resistant | Low | Prostate Cancer | Homo sapiens | |
Network
Due to slow loading speeds, networks with more than 100 edges will not be displayed.
Drug-reponse_GEO
| Compound | ncRNA | ncRNA Type | Pattern | log2FC | p-value | Detail |
|---|---|---|---|---|---|---|
| Cisplatin | H19 | lncRNA | resistant | 1.933 | 7.34e-4 | |
| Temozolomide | H19 | lncRNA | sensitive | -1.463 | NA | |
| Cisplatin | H19 | lncRNA | sensitive | -1.410 | 0.007 | |
| Cisplatin | H19 | lncRNA | resistant | 1.922 | 8.83e-4 | |
| Cisplatin | H19 | lncRNA | sensitive | -3.643 | 3.61e-6 | |
| Cisplatin | H19 | lncRNA | sensitive | -1.136 | NA | |
| Temozolomide | H19 | lncRNA | sensitive | -0.615 | 0.006 | |
| Temozolomide | H19 | lncRNA | sensitive | -2.821 | 2.30e-7 | |
| Cisplatin | H19 | lncRNA | sensitive | -2.047 | NA | |
| Paclitaxel | H19 | lncRNA | sensitive | -0.845 | 1.07e-4 | |
| Temozolomide | H19 | lncRNA | sensitive | -0.357 | 0.019 | |
| Paclitaxel | H19 | lncRNA | sensitive | -1.133 | 4.49e-4 | |
| Doxorubicin | H19 | lncRNA | sensitive | -7.321 | 1.23e-7 | |
| Tamoxifen | H19 | lncRNA | sensitive | -0.540 | 0.033 | |
| Paclitaxel | H19 | lncRNA | sensitive | -0.925 | 2.23e-4 | |
| Cisplatin | H19 | lncRNA | sensitive | -2.030 | NA | |
| Cisplatin | H19 | lncRNA | sensitive | -1.981 | 1.66e-4 | |
| Cisplatin | H19 | lncRNA | sensitive | -3.993 | 2.44e-7 | |
| Cisplatin | H19 | lncRNA | resistant | 2.091 | 1.06e-4 | |
| Cisplatin | H19 | lncRNA | sensitive | -3.511 | NA | |
| Temozolomide | H19 | lncRNA | sensitive | -2.211 | 0.004 | |
| Temozolomide | H19 | lncRNA | resistant | 0.631 | 0.001 | |
| Cisplatin | H19 | lncRNA | sensitive | -2.795 | NA | |
| Tamoxifen+Fulvestrant | H19 | lncRNA | resistant | 0.462 | 0.035 | |
| Tamoxifen | H19 | lncRNA | sensitive | -0.573 | 0.014 | |
| Paclitaxel | H19 | lncRNA | sensitive | -0.711 | 2.92e-4 | |
| Fluorouracil | H19 | lncRNA | resistant | 4.014 | 5.00e-5 | |
| Temozolomide | H19 | lncRNA | sensitive | -1.919 | 1.14e-6 | |
| Doxorubicin | H19 | lncRNA | sensitive | -0.650 | 0.041 | |
| Pazopanib | H19 | lncRNA | sensitive | -7.650 | 3.70e-8 | |
| Vincristine | H19 | lncRNA | sensitive | -4.772 | NA | |
| Doxorubicin | H19 | lncRNA | resistant | 1.740 | 0.010 | |
| Gefitinib | H19 | lncRNA | resistant | 1.389 | 0.005 | |
Network
Due to slow loading speeds, networks with more than 100 edges will not be displayed.
Drug-reponse_NCI60
No result!
Drug-reponse_CCLE
| Compound | ncRNA | Symbol | pattern | log2FC | p-value | Detail | |
|---|---|---|---|---|---|---|---|
| EHT 1864 | H19 | sensitive | sensitive | -1.5026 | 0.0379 | ||
| Elesclomol | H19 | resistant | resistant | 3.3622 | 0.0007 | ||
| Vismodegib | H19 | sensitive | sensitive | -3.3581 | 0.0392 | ||
| Motesanib | H19 | sensitive | sensitive | -3.3641 | 0.0423 | ||
| Elesclomol | H19 | sensitive | sensitive | -3.6482 | 0.0237 | ||
| PAC-1 | H19 | resistant | resistant | 3.5025 | 0.0418 | ||
Network
Due to slow loading speeds, networks with more than 100 edges will not be displayed.
Drug-target_Curated
| Compound | ncRNA | ncRNA Type | Pattern | Throughput | Phenotype | Species | Detail |
|---|---|---|---|---|---|---|---|
| 2,3,7,8-Tetrachlorodibenzo-P-dioxin | H19 | lncRNA | down-regulated | Low | Normal | Mus musculus | |
| Curcumin | H19 | lncRNA | down-regulated | Low | Colorectal Cancer | Homo sapiens | |
| Diethyl 1,4-Dihydro-2,4,6,-Trimethyl-3,5-Pyridinedicarboxylate | H19 | lncRNA | up-regulated | High | Normal | Mus musculus | |
| Diethyl 1,4-Dihydro-2,4,6,-Trimethyl-3,5-Pyridinedicarboxylate | H19 | lncRNA | up-regulated | Low | Normal | Mus musculus | |
| Metformin | H19 | lncRNA | down-regulated | Low | Endometrial Cancer | Homo sapiens | |
| Carboplatin + Docetaxel | H19 | lncRNA | down-regulated | Low | Ovarian Cancer | Homo sapiens | |
| Panobinostat | H19 | lncRNA | up-regulated | High | Nephroblastoma | Homo sapiens | |
| Phenformin | H19 | lncRNA | down-regulated | Low | Glioma | Homo sapiens | |
| Bleomycin | H19 | lncRNA | up-regulated | Low | Normal | Mus musculus | |
| Paclitaxel | H19 | lncRNA | up-regulated | Low | Breast Cancer | Homo sapiens | |
| Cisplatin | H19 | lncRNA | up-regulated | Low | Non-Small Cell Lung Cancer | Homo sapiens | |
| Methotrexate | H19 | lncRNA | up-regulated | Low | Colorectal Cancer | Homo sapiens | |
| Aspirin | H19 | lncRNA | down-regulated | Low | Breast Cancer | Homo sapiens | |
| Huaier Extract | H19 | lncRNA | down-regulated | Low | Breast Cancer | Homo sapiens | |
| Vorinostat | H19 | lncRNA | down-regulated | Low | Thyroid Cancer | Homo sapiens | |
| Panobinostat | H19 | lncRNA | up-regulated | Low | Thyroid Cancer | Homo sapiens | |
| Trichostatin A | H19 | lncRNA | up-regulated | Low | Thyroid Cancer | Homo sapiens | |
| Trichostatin A | H19 | lncRNA | down-regulated | Low | Thyroid Cancer | Homo sapiens | |
| Vorinostat | H19 | lncRNA | up-regulated | Low | Thyroid Cancer | Homo sapiens | |
| Panobinostat | H19 | lncRNA | down-regulated | Low | Thyroid Cancer | Homo sapiens | |
| Aspirin | H19 | lncRNA | down-regulated | Low | Papillary Thyroid Cancer | Homo sapiens | |
| Ginsenoside Rg3 | H19 | lncRNA | down-regulated | High | Ovarian Cancer | Homo sapiens | |
| Synthetic Preimplantation Factor | H19 | lncRNA | up-regulated | Low | Duchenne Muscular Dystrophy | Homo sapiens | |
| Atorvastatin | H19 | lncRNA | up-regulated | Low | Acute Myocardial Infarction | Rattus norvegicus | |
| Metformin | H19 | lncRNA | down-regulated | Low | Preeclampsia | Rattus norvegicus | |
| Isodeoxyelephantopin | H19 | lncRNA | down-regulated | Low | Breast Cancer | Homo sapiens | |
| Metformin | H19 | lncRNA | down-regulated | Low | Ischemia/Reperfusion-Induced Oxidative Stress Injury | Mus musculus | |
| Alaxin | H19 | lncRNA | down-regulated | Low | Liver Fibrosis | Mus musculus | |
| Metformin | H19 | lncRNA | down-regulated | Low | Diabetic Nephropathy | Mus musculus | |
| Epoxyazadiradione | H19 | lncRNA | down-regulated | Low | Head And Neck Squamous Cell Carcinoma | Homo sapiens | |
| Levonorgestrel | H19 | lncRNA | up-regulated | Low | Adenomyosis | Homo sapiens | |
| Deoxyelephantopin | H19 | lncRNA | down-regulated | Low | Uterine Leiomyoma | Homo sapiens | |
| Lipopolysaccharide | H19 | lncRNA | up-regulated | Low | Spinal Cord Injury | Mus musculus | |
| Pravastatin | H19 | lncRNA | up-regulated | High | Atherosclerosis | Homo sapiens | |
| Ginsenoside Rb3 | H19 | lncRNA | up-regulated | Low | Smoke-Induced Lung Injury | Mus musculus | |
| Estrogen | H19 | lncRNA | up-regulated | Low | Normal | Homo sapiens | |
| Gingerol | H19 | lncRNA | up-regulated | Low | Myocardial Ischemia/Reperfusion Injury | Mus musculus | |
| Imatinib | H19 | lncRNA | down-regulated | Low | Gastrointestinal Stromal Tumor | Homo sapiens | |
| Hesperetin | H19 | lncRNA | down-regulated | Low | Breast Cancer | Homo sapiens | |
| Exendin-4 | H19 | lncRNA | up-regulated | High | Steatosis | Homo sapiens | |
| Chrysin | H19 | lncRNA | down-regulated | Low | Gastric Cancer | Homo sapiens | |
| Melatonin | H19 | lncRNA | up-regulated | Low | Normal | Rattus norvegicus | |
| Curcumin + N-N-Butyl Haloperidol Iodide | H19 | lncRNA | down-regulated | Low | Hepatocellular Carcinoma | Homo sapiens | |
| Quercetin | H19 | lncRNA | up-regulated | Low | Osteogenic Differentiation | Homo sapiens | |
| Nimbolide | H19 | lncRNA | down-regulated | Low | Breast Cancer | Homo sapiens | |
Network
Due to slow loading speeds, networks with more than 100 edges will not be displayed.
Drug-target_GEO
| Compound | ncRNA | ncRNA Type | Pattern | log2FC | p-value | Detail |
|---|---|---|---|---|---|---|
| Acriflavine | H19 | lncRNA | up-regulated | 4.846 | 9.89e-12 | |
| Cisplatin | H19 | lncRNA | down-regulated | -1.488 | NA | |
| Cisplatin | H19 | lncRNA | down-regulated | -1.351 | 1.93e-4 | |
| Bleomycin+Oxozeaenol | H19 | lncRNA | down-regulated | -1.325 | 0.002 | |
| Cisplatin | H19 | lncRNA | down-regulated | -1.456 | 4.64e-6 | |
| Cisplatin | H19 | lncRNA | down-regulated | -1.456 | 4.64e-6 | |
| Bleomycin | H19 | lncRNA | down-regulated | -1.277 | 0.002 | |
| Galangin | H19 | lncRNA | down-regulated | -6.763 | NA | |
| Cisplatin | H19 | lncRNA | down-regulated | -1.351 | 5.88e-4 | |
| Beta-Elemene | H19 | lncRNA | up-regulated | 6.030 | 0.014 | |
| Cisplatin | H19 | lncRNA | down-regulated | -2.043 | 0.016 | |
| Berberine | H19 | lncRNA | up-regulated | 1.163 | 0.019 | |
| Clofoctol | H19 | lncRNA | up-regulated | 0.393 | 0.003 | |
| Clofoctol | H19 | lncRNA | up-regulated | 2.198 | 1.24e-8 | |
| Sulfatide | H19 | lncRNA | up-regulated | 1.479 | 0.045 | |
| Cisplatin | H19 | lncRNA | down-regulated | -1.602 | 0.006 | |
| Bleomycin+Oxozeaenol | H19 | lncRNA | down-regulated | -1.299 | 0.003 | |
| Cisplatin | H19 | lncRNA | down-regulated | -1.230 | 0.003 | |
| Cisplatin | H19 | lncRNA | down-regulated | -1.630 | 0.005 | |
| Daidzein | H19 | lncRNA | down-regulated | -0.445 | 0.032 | |
| LEE011 | H19 | lncRNA | down-regulated | -0.498 | 4.23e-4 | |
| Bleomycin+Oxozeaenol | H19 | lncRNA | down-regulated | -1.811 | 1.81e-4 | |
| Trichostatin A | H19 | lncRNA | down-regulated | -1.094 | 0.002 | |
| Cisplatin | H19 | lncRNA | down-regulated | -1.448 | 4.08e-5 | |
| Berberine | H19 | lncRNA | up-regulated | 0.915 | 0.032 | |
| Cisplatin | H19 | lncRNA | down-regulated | -1.450 | NA | |
| Galangin | H19 | lncRNA | up-regulated | 1.714 | 0.021 | |
| Cisplatin | H19 | lncRNA | down-regulated | -1.215 | 0.003 | |
| Panobinostat | H19 | lncRNA | up-regulated | 1.502 | NA | |
| Bleomycin+SB203580 | H19 | lncRNA | down-regulated | -2.360 | 0.021 | |
| Clofoctol | H19 | lncRNA | up-regulated | 0.521 | 5.72e-4 | |
| Clofoctol | H19 | lncRNA | up-regulated | 1.996 | 2.80e-8 | |
| Jiangtang Tiaozhi Recipe | H19 | lncRNA | up-regulated | 0.343 | 0.004 | |
| Beta-Elemene | H19 | lncRNA | up-regulated | 2.615 | 0.009 | |
| Jiangtang Tiaozhi Formular | H19 | lncRNA | up-regulated | 0.308 | 0.024 | |
| Trichostatin A | H19 | lncRNA | down-regulated | -1.244 | 0.012 | |
| Cisplatin | H19 | lncRNA | down-regulated | -1.947 | 0.024 | |
| Ginsenoside Rg3 | H19 | lncRNA | down-regulated | -1.053 | 1.93e-10 | |
| Chloroquine Phosphate | H19 | lncRNA | up-regulated | 2.227 | NA | |
| Decitabine+Trichostatin A | H19 | lncRNA | up-regulated | 1.561 | NA | |
| Androstanolone | H19 | lncRNA | down-regulated | -1.646 | NA | |
| 5alpha-Hydroxytriptolide | H19 | lncRNA | up-regulated | 0.622 | 0.045 | |
| 5alpha-Hydroxytriptolide | H19 | lncRNA | down-regulated | -0.732 | 0.046 | |
Network
Due to slow loading speeds, networks with more than 100 edges will not be displayed.
Drug-target_CMap